IP Library Granted Patent US 10,198,552
Granted Patent B2
US 10,198,552 · App. 14/361,998 · Granted Feb 5, 2019

Method of diagnosis of fibrotic diseases

Inventor: Thierry Poynard (Paris, FR)
Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS; BIOPREDICTIVE
G06F19/18C12Q1/48G01N33/5091G06F19/00G16H50/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,198,552
App. No.
14/361,998
Granted
Feb 5, 2019
Kind
B2
Abstract

The present invention relates to a new diagnosis method in the field of hepatology, combining measurement of serum markers and of liver elasticity.

Claims (35)

1. A method for treating liver cirrhosis in a patient suffering from liver fibrosis comprising the steps of:

a) measuring values of alpha2-macroglobulin, haptoglobin, apolipoprotein-A1, total bilirubin, and gamma-glutamyl-transpeptidase (GGT) in serum or plasma of said patient, and combining said values through a first logistic function including said markers, age, and sex of said patient,

wherein said first logistic function is 4.467×Log(Alpha2Macroglobulin (g/l))−1.357×Log(Haptoglobin (g/l))+1.017×Log(GGT (IU/l))+0.0281×Age (in years)+1.737 ×Log(Bilirubin (μmol/l))−1.184×ApoA1 (g/l)+0.301×Sex (female=0, male=1)−5.540, and obtaining a first index

b) measuring liver stiffness for said patient by Vibration Controlled Transient Elastography and obtaining a second index,

c) combining said first and second index through a second logistic function in order to obtain a final index,

wherein said second logistic function is a1+a2×[first index] +a3×[second index] wherein

a1 is comprised between −9.27 and −9.07;

a2 is comprised between 3.08 and 3.1; and

a3 is comprised between 5.67 and 5.87;

d) diagnosing the level of liver cirrhosis in said patient based on the final index; and

e) providing the patient with appropriate treatment depending on its level of liver cirrhosis.

2. A method for treating a patient suffering from advanced liver fibrosis comprising the steps of:

a) measuring values of alpha2-macroglobulin, haptoglobin, apolipoprotein-A1, total bilirubin, and gamma-glutamyl-transpeptidase (GGT) in serum or plasma of said patient, and combining said values through a first logistic function including said markers, age, and sex of said patient, wherein said first logistic function is 4.467×Log(Alpha2Macroglobulin (g/l))−1.357×Log(Haptoglobin (g/l))+1.017×Log(GGT (IU/1))+0.0281×Age (in years)+1.737×Log(Bilirubin (μmol/l))−1.184×ApoA1 (g/l)+0.301×Sex (female=0, male=1)−5.540, and obtaining a first index

b) measuring liver stiffness for said patient by Vibration Controlled Transient Elastography and obtaining a second index,

c) combining said first and second index through a second logistic function in order to obtain a final index, wherein said second logistic function is b1+b2×[first index] +b3×[second index] wherein

b1 is comprised between 2.35 and 2.55;

b2 is comprised between 2.8 and 3; and

b3 is comprised between 2.25 and 2.45;

d) diagnosing the level of liver fibrosis in said patient based on the final index; and

e) treating the patient according to the level of liver fibrosis.

3. The method of claim 1 , wherein said second logistic function is −9.1753+3.0893×[first index] +5.7786×[second index].

4. The method of claim 2 , wherein said second logistic function is 2.4518+2. 8935×[first index] +2.3657×[second index].

5. A method for treating liver fibrosis or cirrhosis in a patient comprising the steps of:

a) measuring values of alpha2-macroglobulin, haptoglobin, apolipoprotein-A1, total bilirubin, and gamma-glutamyl-transpeptidase (GGT) in serum or plasma of said patient, and combining said values through a first logistic function including said markers, age, and sex of said patient,

wherein said first logistic function is 4.467×Log(Alpha2Macroglobulin (g/l))−1.357×Log(Haptoglobin (g/l))+1.017×Log(GGT (IU/1))+0.0281×Age (in years)+1.737×Log(Bilirubin (μmol/l))−1.184×ApoA1 (g/l)+0.301×Sex (female=0, male=1)−5.540, and obtaining a first index

b) measuring liver stiffness for said patient by Vibration Controlled Transient Elastography and obtaining a second index,

c) combining said first and second index through a second logistic function in order to obtain a final index,

wherein said second logistic function is a1+a2×[first index] +a3×[second index] wherein

a1 is comprised between −−9.27 and −9.07;

a2 is comprised between 3.08 and 3.1; and

a3 is comprised between 5.67 and 5.87,

d) diagnosing the level of liver cirrhosis in said patient based on the final index, and

e) classifying said patient as METAVIR F4 if the result of the second logistic function is higher or equal to 0.25, and

f) if the result of the second logistic function is lower than 0.25, classifying said patient with a METAVIR score using the result of the first logistic function, and

g) treating the patient according to the level of liver fibrosis or cirrhosis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2014
From: POYNARD, THIERRY
To: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; BIOPREDICTIVE
Reel/Frame 033344/0759 →
Priority Claims (1)
EP 11306611 · Dec 2, 2011 · regional
Continuity (1)
Related Publication 20140329260A1 · Nov 6, 2014